scholarly journals A laktátdehidrogenáz (LDH) prognosztikai jelentősége az onkológiában

2017 ◽  
Vol 158 (50) ◽  
pp. 1977-1988 ◽  
Author(s):  
Dániel Deme ◽  
András Telekes
Keyword(s):  
Cell Proliferation ◽  
Lactate Dehydrogenase ◽  
Immune Responses ◽  
Malignant Cells ◽  
Malignant Diseases ◽  
Adaptive Immune Responses ◽  
Reversible Process ◽  
Baseline Serum ◽  
Adaptive Immune ◽  
Lactate Formation

Abstract: Glycolysis is increased in most of the malignant cells, providing the largest proportion of energy needed for cell proliferation. Lactate dehydrogenase (LDH) catalyses the reversible process of pyruvate to lactate in anaerobic condition. LDHA isoenzyme expressed mainly by malignant cells, significantly increases lactate formation. Lactate induces the proliferation of oxygenated malignant cells, angiogenesis, and inhibits the innate and adaptive immune responses. Baseline serum LDH elevation correlates with shorter survival. The authors review the relevant studies exploring the correlation between LDH elevation and the prognosis of malignant diseases. Orv Hetil. 2017; 158(50): 1977–1988.

Engaging the NKG2D Receptor with a Novel Bispecific Protein (ULBP2-antiCD138) Activates NK Cells and Has Potent Antitumor Activity Against Human Multiple Myeloma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5157-5157
Author(s):  
Elke Pogge von Strandmann ◽  
Michael Hallek ◽  
Andreas Engert
Keyword(s):  
Multiple Myeloma ◽  
Immune Responses ◽  
Nk Cells ◽  
Clinical Investigation ◽  
Human Peripheral Blood ◽  
Malignant Cells ◽  
Adaptive Immune Responses ◽  
Nude Mouse Model ◽  
Ifn Gamma ◽  
Adaptive Immune

Abstract NK cells, a component of the innate immune system, attack virus-infected and malignant cells without prior antigen stimulation, mediate cellular cytotoxicity and produce cytokines such as interferon gamma (IFN-gamma) upon stimulation. There is growing evidence that NK cells also participate directly in adaptive immune responses, mainly by cross-talk with dendritic cells. One key factor responsible for the activation of innate and adaptive immune responses is NKG2D, a stimulatory receptor expressed on natural killer cells that binds to cellular ligands on malignant cells. Therefore we designed a recombinant NK receptor ligand (ULBP2) fused to an antibody (BB4) detecting the tumor antigen CD138 which is overexpressed on a variety of malignancies including multiple myeloma (MM). The major findings were that (1) ULBP2-BB4 bound both NK cells and tumor cells, (2) triggered NK-mediated cell lysis of CD138+ malignant cell lines and primary MM cells in the allogenic and autologous setting, (3) activated IFN-gamma secretion of NK cells exposed to immobilized protein, and (4) the co-therapy with ULBP-BB4 and human peripheral blood lymphocytes abrogated the tumor growth in a nude mouse model with subcutaneously growing MM cells. This is the first report on the design, expression, purification and functional pre-clinical investigation of a recombinant NKG2D ligand. The results suggest not only a potential clinical use of this novel construct in patients with MM, but might also offer an innovative therapy approach which is based on NKG2D engagement transferable to other malignancies.

scholarly journals T cell proliferation and adaptive immune responses are critically regulated by protein phosphatase 4

Cell Cycle ◽  
2016 ◽  
Vol 15 (8) ◽  
pp. 1073-1083 ◽  
Author(s):  
Fang-Hsuean Liao ◽  
Wan-Yi Hsiao ◽  
Yu-Chun Lin ◽  
Yi-Chiao Chan ◽  
Ching-Yu Huang
Keyword(s):  
Cell Proliferation ◽  
T Cell ◽  
Immune Responses ◽  
Protein Phosphatase ◽  
T Cell Proliferation ◽  
Adaptive Immune Responses ◽  
Adaptive Immune
Sign in / Sign up

Export Citation Format

Share Document